Skip to content
PubMed This is a summary of 13 peer-reviewed journal articles Updated
Dermatology · Drug-Induced Subacute Cutaneous Lupus Erythematosus

What Medications Can Trigger Subacute Cutaneous Lupus?

At a Glance

Several medications, especially proton pump inhibitors, thiazide diuretics, some blood pressure drugs, and terbinafine, can trigger a sun-sensitive subacute cutaneous lupus rash. Do not stop a suspected medicine yourself; a clinician should guide evaluation and any change.

Drug-induced subacute cutaneous lupus erythematosus (DI-SCLE) can be triggered by several common prescription medications. Medications most frequently associated with DI-SCLE include proton pump inhibitors (PPIs) for acid reflux, certain blood pressure medications like thiazide diuretics and calcium channel blockers, and the oral antifungal terbinafine [1][2][3]. The timing of the rash varies widely—it can appear weeks, months, or even years after starting a medication [4][5]. The primary treatment is for a doctor to supervise stopping or switching the suspected drug, but it is critical that you never stop a prescribed medication without medical guidance [3][2].

Urgent Warning: When to Seek Immediate Care

Some drug-related rashes can be severe or life-threatening and require immediate medical attention. Go to an urgent care or emergency room if your rash is spreading rapidly, involves skin peeling or painful blisters, or is accompanied by sores in the mouth, eyes, or genitals. You should also seek immediate care if you develop a fever, facial swelling, breathing difficulties, or feel severely unwell. These are not typical signs of SCLE and could indicate a more dangerous reaction.

Common Everyday Medications Associated with Skin Lupus

While the overall risk for any individual patient is low, research identifies several classes of medications known to trigger DI-SCLE.

Acid Reflux Medications (Proton Pump Inhibitors)

Proton pump inhibitors, commonly known as PPIs, reduce stomach acid and are strongly associated with drug-induced skin lupus [6][7]. Examples include omeprazole, pantoprazole, and esomeprazole [5][8]. In some cases, the skin reaction might not appear until you have been taking the medication for several months or even up to a year [5][6]. Because there may be a “class effect” (meaning similar drugs could trigger the same reaction), your doctor might recommend trying a different type of acid reflux treatment rather than just switching to another PPI [6].

Blood Pressure Medications

Certain medications used to treat high blood pressure and fluid retention are known triggers [9]:

  • Thiazide diuretics: Often called “water pills,” these help the body remove extra salt and water and are repeatedly identified as common culprits [1][2].
  • Calcium channel blockers: Medications such as amlodipine, which relax blood vessels, have been linked to the condition [9][10].
  • Beta blockers: These lower blood pressure by slowing the heart rate and have also been reported in some cases [9].

Terbinafine

Terbinafine, an oral antifungal medication often prescribed for fungal nail infections, is a well-documented cause of DI-SCLE [3]. While the rash typically begins around five weeks after starting the drug, the timeframe varies greatly and this does not mean other antifungals carry the exact same risk [3].

Other Medications

Other drugs associated with DI-SCLE include statins (for high cholesterol) and certain antiepileptics (anti-seizure medications) [1]. Certain chemotherapy or targeted immune therapies used in cancer treatment can also trigger lupus-like rashes [11]. Never stop cancer treatments or anti-seizure medications without coordinating with your specialist.

Diagnosing Drug-Induced Skin Lupus

Diagnosing drug-induced SCLE can be challenging because it looks identical to non-drug-induced (idiopathic) SCLE. Idiopathic simply means no medication cause has been identified.

  • Appearance: The rash usually appears as scaly, ring-shaped (annular), or coin-shaped patches that are red and inflamed [5][12]. It worsens with sunlight and most frequently appears on the face, neck, chest, back, and arms, though drug-induced cases can sometimes be more widespread [6][1].
  • Testing: Your doctor may order a blood test to look for an anti-Ro (SSA) antibody, a common marker in both drug-induced and non-drug-induced SCLE [5][3]. They may also take a skin biopsy (a small sample of skin examined under a microscope). While these tests help confirm that the rash is SCLE, no test can prove that a specific drug caused it. Diagnosis relies on piecing together the timeline of your medications and seeing if the rash improves when the suspected drug is stopped [2][13].
  • Systemic Symptoms: Tell your doctor if you experience new joint pain, marked fatigue, chest pain, shortness of breath, or dark urine. While DI-SCLE primarily affects the skin, your doctor will want to ensure the reaction isn’t affecting your internal organs.

Sun Protection is Essential

Because ultraviolet (UV) light can worsen the rash, strict sun protection is crucial while your skin heals:

  • Apply a broad-spectrum sunscreen with SPF 30 or higher daily.
  • Seek shade and avoid intense midday sun or tanning beds.
  • Wear protective clothing, such as long sleeves and wide-brimmed hats.

What to Do If You Suspect a Medication

If you suspect a daily medication is causing your rash, do not stop taking it on your own. Abruptly stopping blood pressure medications or other essential drugs can be dangerous.

  1. Consult your prescribing doctor or dermatologist: Work with them to evaluate your medication timeline [2]. Bring a complete list of everything you take, including over-the-counter drugs and supplements, along with their start dates and any recent dose changes.
  2. Supervised withdrawal: If your medical team suspects a specific drug, they will create a safe plan to taper off the medication or switch you to a safer alternative.
  3. Recovery timeline: After stopping the trigger, the rash usually begins to improve within a few weeks, but complete clearing can take several weeks to a few months [3][5]. Your doctor may prescribe topical steroids (anti-inflammatory creams applied to the skin) or other treatments to help speed up healing while the drug leaves your system [5]. If the rash does not improve after a few months, your doctor will need to reassess the diagnosis.

Common questions in this guide

Which medications are most often linked to drug-induced subacute cutaneous lupus?
The medications most often associated include proton pump inhibitors such as omeprazole, pantoprazole, and esomeprazole; thiazide diuretics; calcium channel blockers; and oral terbinafine. Beta blockers, statins, some anti-seizure medicines, and certain cancer therapies have also been reported.
How long after starting a medication can the lupus rash appear?
The rash may appear within weeks, after several months, or even years after a medicine is started. The timing alone cannot prove which drug caused it, so a clinician reviews the full medication history and changes in dose.
Should I stop a medication if I think it caused my rash?
No. Do not stop a prescription on your own, because abruptly stopping some medicines can be dangerous. Contact the prescribing clinician or dermatologist, who can plan a supervised taper or switch if needed.
How is drug-induced subacute cutaneous lupus diagnosed?
A clinician examines the rash and may order an anti-Ro (SSA) antibody blood test and a skin biopsy. These tests can support a diagnosis of subacute cutaneous lupus, but no test by itself proves that a particular medicine caused it; the medication timeline and improvement after supervised withdrawal are also considered.
What does the rash from drug-induced SCLE usually look like?
It often causes red, inflamed, scaly patches that may be ring-shaped or coin-shaped and become worse with sunlight. Common areas include the face, neck, chest, back, and arms, although a medication-related rash can be more widespread.
When is a medication-related rash an emergency?
Seek immediate care for a rapidly spreading rash, skin peeling, painful blisters, sores in the mouth, eyes, or genitals, fever, facial swelling, trouble breathing, or severe illness. These features are not typical of SCLE and can signal a more dangerous drug reaction.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which of my medications, including over-the-counter drugs, is the most likely suspect based on when my rash started?
  2. 2.How will we safely taper off or replace the suspected medication?
  3. 3.If we stop the drug, how long should we wait to see improvement before we reassess the diagnosis?
  4. 4.Do I need any blood tests or a skin biopsy to confirm the type of rash, and what other conditions could this be?
  5. 5.What severe symptoms should prompt me to seek same-day or urgent medical care?
  6. 6.If the rash clears, should I avoid this specific medication or its entire class permanently?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (13)
  1. 1

    Drug-induced cutaneous lupus erythematosus: 88 new cases.

    Laurinaviciene R, Sandholdt LH, Bygum A

    European journal of dermatology : EJD 2017; (27(1)):28-33 doi:10.1684/ejd.2016.2912.

    PMID: 27799135
  2. 2

    [When drugs induce cutaneous lupus erythematosus].

    Skovmøller KB, Bygum A

    Ugeskrift for laeger 2018; (180(41)).

    PMID: 30327081
  3. 3

    Analysis of clinical characteristics of terbinafine-induced subacute cutaneous lupus erythematosus.

    He Y, Fan Z, Guo Y, et al.

    Expert opinion on drug safety 2025; (24(7)):847-851 doi:10.1080/14740338.2024.2390644.

    PMID: 39136391
  4. 4

    Systemic 5-fluorouracil induced lupus erythematosus: a review of the literature.

    Shakhbazova A, Marsch AF

    Dermatology online journal 2019; (25(11)).

    PMID: 32045142
  5. 5

    Proton pump inhibitors-related subacute cutaneous lupus erythematosus: Clinical characteristics, management, and outcome.

    Deng Z, Guo A, Wu C, Wang C

    Journal of cosmetic dermatology 2022; (21(12)):7202-7208 doi:10.1111/jocd.15450.

    PMID: 36214602
  6. 6

    Proton pump inhibitor induced subacute cutaneous lupus erythematosus: Clinical characteristics and outcomes.

    Poh YJ, Alrashid A, Sangle SR, et al.

    Lupus 2022; (31(9)):1078-1083 doi:10.1177/09612033221104237.

    PMID: 35635045
  7. 7

    Drug-Induced Subacute Cutaneous Lupus Erythematosus Associated with Proton Pump Inhibitors.

    Aggarwal N

    Drugs - real world outcomes 2016; (3(2)):145-154 doi:10.1007/s40801-016-0067-4.

    PMID: 27398293
  8. 8

    Proton Pump Inhibitor Induced Subacute Cutaneous Lupus Erythematosus: A Case Series of 7 Patients and Brief Review of Literature.

    Kaur S, Singla P, Kaur S, et al.

    Indian dermatology online journal 2022; (13(1)):64-72 doi:10.4103/idoj.idoj_237_21.

    PMID: 35198470
  9. 9

    Cutaneous effects of antihypertensive drugs.

    Baccino D, Merlo G, Cozzani E, et al.

    Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia 2020; (155(2)):202-211 doi:10.23736/S0392-0488.19.06360-0.

    PMID: 31195782
  10. 10

    Amlodipine-Induced Subacute Cutaneous Lupus Erythematosus Localized to Non-Sun-Exposed Areas.

    Mizuta T, Kato M

    Case reports in dermatology 2022; (14(1)):71-76 doi:10.1159/000524001.

    PMID: 35496508
  11. 11

    Drug-induced lupus erythematosus: an update on drugs and mechanisms.

    He Y, Sawalha AH

    Current opinion in rheumatology 2018; (30(5)):490-497 doi:10.1097/BOR.0000000000000522.

    PMID: 29870500
  12. 12

    Topical drug-induced subacute cutaneous lupus erythematosus isolated to the hands.

    Ramachandran SM, Leventhal JS, Franco LG, et al.

    Lupus science & medicine 2017; (4(1)):e000207 doi:10.1136/lupus-2017-000207.

    PMID: 28331627
  13. 13

    Are there distinct clinical and pathological features distinguishing idiopathic from drug-induced subacute cutaneous lupus erythematosus? A European retrospective multicenter study.

    Guicciardi F, Atzori L, Marzano AV, et al.

    Journal of the American Academy of Dermatology 2019; (81(2)):403-411 doi:10.1016/j.jaad.2019.02.009.

    PMID: 30763648

This page is for informational purposes only and does not replace medical advice. Do not stop or change a suspected medication without guidance from your prescribing clinician or dermatologist.

Get notified when new evidence is published on Cutaneous lupus erythematosus.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.